Safety Reading Notes

Read safety context beside the research guide.

The DHEA / synaptamide source set includes safety-context rows around DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 22959887

Mechanistic research summary: insufficient (2), mechanistic or pharmacological (3)

PubMed For Dummies Article

DHEA / synaptamide Evidence Review: the long-form source walk-through

Quick read
  • DHEA / synaptamide currently has 5 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 22959887
  • The evidence classes most visible in the row language are mechanistic or pharmacological (3), and insufficient (2). PMID 27809877
  • The study-design language most visible in the row language is Animal study (3), and Narrative or expert review (2). PMID 23570577
  • The repeated topics are DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physi... (5), which tells the reader where to start opening PubMed and DOI links. PMID 27759003

Start with the research question

DHEA / synaptamide is built from 5 source-backed evidence row(s) and 5 research source(s). The current evidence classes read as mechanistic or pharmacological (3), and insufficient (2), and the study-design language most often reads as Animal study (3), and Narrative or expert review (2). PMID 22959887

The row-level question is not simply whether DHEA / synaptamide is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physi... (5). PMID 22959887

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 21810478

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 22959887

Mechanistic evidence 3 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 27809877

Limits and uncertainty 2 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 23570577

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 27759003

Where this page has the most source density

The largest bucket surfaced for this page is DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is the next evidence bucket, which gives readers another way to see what the literature repeatedly circles. PMID 22959887

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 22959887

Bucket chapters: what the literature is circling

DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms

5 research sources 5 rows (1167-1171) Mechanistic research summary: insufficient (2), mechanistic or pharmacological (3)

DHEA / synaptamide appears in rows studying DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms. It currently draws from 5 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 22959887

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 22959887

  • Evidence row 1167

    DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome m... PMID 22959887

  • Evidence row 1171

    DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study... PMID 21810478

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (3 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 22959887

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 22959887

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 21810478
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 22959887
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 27809877

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 22959887

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 22959887

Source-reading checklist for DHEA / synaptamide

  1. Open the linked PubMed or DOI record. PMID 23570577
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 27759003
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 21810478
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 22959887
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 27809877

Source Notes

DHEA / synaptamide source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 1167

    DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms). PMID 22959887

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Synaptamide, endocannabinoid-like derivative of docosahexaenoic acid with cannabinoid-independent function.
  2. Evidence row 1168

    DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms). PMID 27809877

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: N-Docosahexaenoylethanolamine ameliorates LPS-induced neuroinflammation via cAMP/PKA-dependent signaling.
  3. Evidence row 1169

    DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms). PMID 23570577

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: N-Docosahexaenoylethanolamine is a potent neurogenic factor for neural stem cell differentiation.
  4. Evidence row 1170

    DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms). PMID 27759003

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Orphan GPR110 (ADGRF1) targeted by N-docosahexaenoylethanolamine in development of neurons and cognitive function.
  5. Evidence row 1171

    DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms). PMID 21810478

    Evidence class: insufficient; Study design: Narrative or expert review. Source: A synaptogenic amide N-docosahexaenoylethanolamide promotes hippocampal development.